AHFS Classification – Drug Assignments
The following describes drug assignments and changes to the AHFS Pharmacologic-Therapeutic Classification©. This is only a partial listing of the AHFS classification system. The full classification, along with a list of drugs covered in AHFS DI and their corresponding classes, is available in the print edition of AHFS and electronically as a dataset that can be licensed. Reproduction, storage on a retrieval system, or transmission of this material or any part thereof in any form or by any means without the express written permission of the American Society of Health-System Pharmacists is prohibited.
Please contact us at ahfs@ashp.org if you have any questions.
AHFS Drug Assignments
| Drug Name | Active Ingredients | Company | Indication | Approval Date | AHFS Class | NDA Type | Appl No |
|---|---|---|---|---|---|---|---|
| Zenbexus | iberdomide | Bristol Myers Squibb | Multiple Myeloma | 08/13/2026 | 10:00 - Antineoplastic Agents | ||
| Tudriqev | vusolimogene oderparepvec-wtpg | Replimune Group, Inc. | Unresectable Advanced Cutaneous Melanoma | 08/06/2026 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | ||
| Orzeyful | oveporexton | Takeda | Underlying Cause of Narcolepsy Type 1 | 08/05/2026 | 28:20.80 - Wakefulness-promoting Agents | ||
| mFLUSIVA | mRNA influenza vaccine | Moderna | seasonal flu in adults aged 50 years and older | 08/05/2026 | 80:12 - Vaccines | ||
| Lytenava | bevacizumab-vikg | Outlook Therapeutics, Inc. | neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. | 07/24/2026 | 52:56 - Vascular Endothelial Growth Factor Antagonists | BLA | 761320 |
| Simtriyo | Centanafadine | Otsuka Pharmaceutical Co., Ltd. | Attention-Deficit Hyperactivity Disorder (ADHD) | 07/24/2026 | 28:20.32 - Respiratory and CNS Stimulants | 1P | 218145 |
| Jideytro | zidesamtinib | GSK | Previously Treated ROS1-Positive Non-Small Cell Lung Cancer | 07/22/2026 | 10:00 - Antineoplastic Agents | ||
| Lipfendra | enlicitide | Merck | Hypercholesterolemia | 07/16/2026 | 24:06.24 - Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors | ||
| Revtorpyk | gedatolisib | Celcuity Inc. | HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer | 07/14/2026 | 10:00 - Antineoplastic Agents | 1P | 219908 |
| Zyogreen | indocyanine green dye | Provepharm | surgical visualisation and precision medicine | 07/10/2026 | 36:68 - Roentgenography | 3S | 218579 |
| Trutakna | Atacicept-vymj | Vera Therapeutics, Inc. | Primary IgA Nephropathy | 07/07/2026 | 90:22 - A Proliferation Inducing Ligand (APRIL) or B cell activating factor (BAFF) Inhibitor Agents | BLA | 761486 |
| Lumvoa | veligrotug-vvze | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 06/26/2026 | 52:08 - Anti-inflammatory Agents | BLA | 761530 |
| Utebzi | tebipenem pivoxil | Spero Therapeutics/GSK | complicated urinary tract infections (cUTI), including pyelonephritis, caused by several susceptible microorganisms in adult patients who have limited or no alternative oral treatment options | 06/17/2026 | 8:12.07.08 - Carbapenems | ||
| Xocova | ensitrelvir | Shionogi & Co., Ltd. | First and Only Oral Option to Help Prevent COVID-19 Following Exposure | 06/01/2026 | 8:18.48 - Coronavirus (COVID-19) | ||
| Zaynich | cefepime and zidebactam | Wockhardt | Complicated Urinary Tract Infections | 05/29/2026 | 8:12.06.16 - Fourth Generation Cephalosporins | 1/4P | 220787 |
| Decnupaz | Pivekimab sunirine-pvzy | AbbVie | Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options | 05/27/2026 | 10:00 - Antineoplastic Agents | BLA/O | 761460 |
| Hepcludex | bulevirtide-gmod | Gilead Sciences, Inc. | Chronic Hepatitis Delta Virus (HDV) | 05/22/2026 | 8:18.42.04 - Entry Inhibitors | BLA/O | 761468 |
| Baxfendy | baxdrostat | AstraZeneca | Hypertension | 05/15/2026 | 24:32.24 - Aldosterone Synthase Inhibitors | 1P | 219878 |
| Beqalzi | Sonrotoclax | BeOne Medicines Ltd. | Relapsed or Refractory Mantle Cell Lymphoma | 05/13/2026 | 10:00 - Antineoplastic Agents | ||
| Veppanu | vepdegestrant | Arvinas, Inc. | ESR1m, ER+/HER2- Advanced Breast Cancer | 05/01/2026 | 10:00 - Antineoplastic Agents | ||
| Otarmeni | lunsotogene parvec-cwha | Regeneron Pharmaceuticals, Inc. | Gene Therapy for Genetic Hearing Loss | 04/23/2026 | 26:12 - Gene Therapy | ||
| Idvynso | doravirine and islatravir | Merck Sharp and Dohme LLC | HIV-1 Infection in Adults | 04/20/2026 | 8:18.08.16 - HIV Nonnucleoside Reverse Transcriptase Inhibitors | 1/4 S | 216964 |
| Foundayo | Orforglipron | Eli Lilly and Company | used in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition | 04/01/2026 | 68:20.06 - Incretin Mimetics | ||
| Kresladi | marnetegragene autotemcel | Rocket Pharmaceuticals, Inc. | Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) | 03/27/2026 | 26:12 - Gene Therapy | ||
| Awiqli | insulin icodec-abae | Novo Nordisk | type 2 diabetes | 03/26/2026 | 68:20.08.16 - Long-acting Insulins | ||
| Lifyorli | Relacorilant | Corcept Therapeutics Inc. | platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer | 03/25/2026 | 10:00 - Antineoplastic Agents | ||
| Avlayah | tividenofusp alfa-eknm | Denali Therapeutics Inc. | Hunter Syndrome (MPS II) | 03/24/2026 | 44:00 - Enzymes | BLA/O | 761485 |
| Icotyde | icotrokinra | Johnson & Johnson | Treatment of Plaque Psoriasis | 03/18/2026 | 84:06.28 - Immunomodulatory Agents | ||
| Lynavoy | Linerixibat | GlaxoSmithKline LLC | cholestatic pruritus in patients with primary biliary cholangitis (PBC) | 03/17/2026 | 56:14 - Cholelitholytic Agents | 1S/O | 220295 |
| Pylarify TruVu | piflufolastat F 18 | Lantheus Holdings, Inc. | positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level | 03/06/2026 | 36:92 - Diagnostic Agents, Miscellaneous | ||
| Loargys | pegzilarginase-nbln | Immedica Pharma US Inc. | hyperargininemia in patients 2 years and older with Arginase 1 Deficiency (ARG1-D) | 02/23/2026 | 44:00 - Enzymes | ||
| Bysanti | milsaperidone | Vanda Pharmaceuticals Inc. | Bipolar I Disorder and Schizophrenia | 02/20/2026 | 28:16.08.04 - Atypical Antipsychotics | ||
| Adquey | difamilast | Acrotech Biopharma Inc. | mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 and older | 02/12/2026 | 84:06.12 - Phosphodiesterase-4 Inhibitors | 1S | 219474 |
| Yuvezzi | carbachol and brimonidine tartrate | Tenpoint Therapeutics, Ltd. | Presbyopia | 01/28/2026 | 52:40.20 - Miotics | 3/4 S | 220142 |
| Zycubo | copper histidinate | Sentynl Therapeutics. | Children With Menkes Disease | 01/12/2026 | 40:12 - Replacement Preparations | 1P/O | 211241 |
| Nereus | tradipitant | Vanda Pharmaceuticals Inc. | Prevention of Motion Sickness | 12/30/2025 | 56:22.32 - Neurokinin-1 Receptor Antagonists | ||
| Yartemlea | narsoplimab-wuug | Omeros Corporation | Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy | 12/24/2025 | 90:20 - Complement Inhibitor Agents | ||
| Myqorzo | aficamten | Cytokinetics, Inc | Symptomatic Obstructive Hypertrophic Cardiomyopathy | 12/19/2025 | 24:04.92 - Cardiac Drugs, Miscellaneous | 219083 | |
| Exdensur | Depemokimab-ulaa | GSK | Severe Asthma with an Eosinophilic Phenotype | 12/16/2025 | 48:10.20 - Interleukin Antagonists | ||
| Lerochol | lerodalcibep-liga | LIB Therapeutics Inc. (LIB) | Adults with Elevated LDL Cholesterol | 12/12/2025 | 24:06.24 - Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors | BLA | 761427 |
| Cardamyst | etripamil | Milestone Pharmaceuticals Inc. | Paroxysmal Supraventricular Tachycardia | 12/12/2025 | 24:04.04.24 - Class IV Antiarrhythmics | ||
| Nuzolvence | Zoliflodacin | Entasis Therapeutics | Gonorrhea | 12/12/2025 | 8:12.28.40 - Spiropyrimidinetrione | 1P | 219491 |
| Waskyra | Etuvetidigene autotemcel | Fondazione Telethon ETS | Wiskott-Aldrich Syndrome | 12/09/2025 | 26:12 - Gene Therapy | ||
| Voyxact | sibeprenlimab-szsi | Otsuka Pharmaceutical, Co. Ltd. | Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression | 11/25/2025 | 90:22 - A Proliferation Inducing Ligand (APRIL) or B cell activating factor (BAFF) Inhibitor Agents | BLA | 761434 |
| Hyrnuo | sevabertinib | Bayer HealthCare Pharmaceuticals Inc. | Non-Squamous Non-Small Cell Lung Cancer | 11/19/2025 | 10:00 - Antineoplastic Agents | 1P/O | 219972 |
| Redemplo | plozasiran | Arrowhead Pharmaceuticals, Inc. | Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome | 11/18/2025 | 24:06.92 - Antilipemic Agents, Miscellaneous | 1S/O | 219947 |
| Komzifti | ziftomenib | Kura Oncology, Inc. | for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. | 11/13/2025 | 10:00 - Antineoplastic Agents | ||
| Kygevvi | doxecitine and doxribtimine | UCB Inc | Thymidine Kinase 2 Deficiency | 11/03/2025 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | 219792 |
| Lynkuet | elinzanetant | Bayer HealthCare Pharmaceuticals, Inc. | Hot Flashes Due to Menopause | 10/24/2025 | 28:92 - Central Nervous System Agents, Miscellaneous | 1S | 219469 |
| Jascayd | Nerandomilast | Boehringer Ingelheim Pharmaceuticals, Inc. | idiopathic pulmonary fibrosis (IPF) | 10/07/2025 | 48:02 - Antifibrotic Agents | 1P/O | 218764 |
| Rhapsido | remibrutinib | Novartis | Chronic Spontaneous Urticaria | 09/30/2025 | 84:06.28 - Immunomodulatory Agents | 1P | 218436 |
| Palsonify | Paltusotine | Crinetics Pharma Inc | Acromegaly in Adults | 09/25/2025 | 68:29.04 - Somatostatin Agonists | 1P | 219070 |
| Inluriyo | imlunestrant | Eli Lilly and Company | Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer | 09/25/2025 | 10:00 - Antineoplastic Agents | ||
| Forzinity | elamipretide | Stealth Biotherapeutics Inc. | Barth syndrome | 09/19/2025 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P | 215244 |
| Keytruda Qlex | pembrolizumab and berahyaluronidase alfa-pmph | Merck | Solid Tumors | 09/19/2025 | 10:00 - Antineoplastic Agents | BLA | 761467 |
| Wayrilz | rilzabrutinib | Sanofi | Immune Thrombocytopenia | 08/29/2025 | 20:92 - Blood Formation, Coagulation, and Thrombosis Agents; Miscellaneous | 1P | 219685 |
| Dawnzera | donidalorsen | Ionis Pharmaceuticals, Inc. | Hereditary Angioedema | 08/21/2025 | 24:48.08 - Kallikrein Inhibitors | 1S/O | 219407 |
| Papzimeos | zopapogene imadenovec-drba | Precigen, Inc. | Recurrent Respiratory Papillomatosis | 08/15/2025 | 26:12 - Gene Therapy | ||
| Brinsupri | brensocatib | Insmed Incorporated | Non-Cystic Fibrosis Bronchiectasis | 08/12/2025 | 48:10.36 - Neutrophil Serine Protease (NSP) Inhibitors | ||
| Hernexeos | zongertinib | Boehringer Ingelheim Pharmaceuticals, Inc. | Previously Treated Patients with HER2-Mutant Advanced NSCLC | 08/08/2025 | 10:00 - Antineoplastic Agents | 1P | 219042 |
| Modeyso | dordaviprone | Chimerix Inc. | Recurrent H3 K27M-Mutant Diffuse Midline Glioma | 08/06/2025 | 10:00 - Antineoplastic Agents | 1/4 P/O | 219876 |
| Vizz | aceclidine ophthalmic solution | LENZ Therapeutics, Inc. | Presbyopia | 07/31/2025 | 52:92 - EENT Drugs, Miscellaneous | 1S | 218585 |
| Sephience | sepiapterin | PTC Therapeutics, Inc. | Treatment of Children and Adults Living with Phenylketonuria | 07/28/2025 | 44:08 - Enzyme Cofactors/Chaperones | 1S/O | 219666 |
| Anzupgo | delgocitinib | LEO Pharma | Chronic Hand Eczema | 07/23/2025 | 84:06.16 - Janus Kinase Inhibitors | ||
| Ekterly | sebetralstat | KalVista Pharmaceuticals, Inc. | First and Only Oral On-demand Treatment for Hereditary Angioedema (HAE) | 07/07/2025 | 24:48.08 - Kallikrein Inhibitors | ||
| Lynozyfic | linvoseltamab-gcpt | Regeneron Pharmaceuticals, Inc. | Relapsed or Refractory Multiple Myeloma | 07/02/2025 | 10:00 - Antineoplastic Agents | BLA | 761400 |
| Zegfrovy | Sunvozertinib | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Treatment for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations as detected with an FDA-approved test following progression on or after platinum-containing chemotherapy | 07/02/2025 | 10:00 - Antineoplastic Agents | 1P | 219839 |
| Andembry | garadacimab-gxii | CSL Behring LLC | Prophylaxis to Prevent Attacks of Hereditary Angioedema | 06/16/2025 | 24:48.12 - Factor XIIa Inhibitors | BLA | 219847 |
| Ibtrozi | taletrectinib | Nuvation Bio Inc. | Advanced ROS1-Positive Non-Small Cell Lung Cancer | 06/11/2025 | 10:00 - Antineoplastic Agents | 1P/O | 219713 |
| Enflonsia | clesrovimab-cfor | Merck | Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants | 06/09/2025 | 8:18.24 - Monoclonal Antibodies | ||
| Widaplik | telmisartan, amlodipine and indapamide | George Medicines | Hypertension | 06/05/2025 | 24:32.08 - Angiotensin II Receptor Antagonists; 24:28.08 - Dihydropyridines; 40:28.24 - Thiazide-like Diuretics | 4S | 219423 |
| Tryptyr | acoltremon | Alcon | Dry Eye Disease | 05/28/2025 | 52:92 - EENT Drugs, Miscellaneous | 1S | 217370 |
| Emrelis | telisotuzumab vedotin-tllv | AbbVie | Non-Small Cell Lung Cancer With High c-Met Protein Overexpression | 05/14/2025 | 10:00 - Antineoplastic Agents | ||
| Avmapki Fakzynja Co-Pack | avutometinib capsules/defactinib tablets | Verastem Oncology | KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer | 05/08/2025 | 10:00 - Antineoplastic Agents | ||
| Zevaskyn | prademagene zamikeracel | Abeona Therapeutics Inc. | Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa | 04/29/2025 | 26:12 - Gene Therapy; 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | ||
| Imaavy | nipocalimab-aahu | Janssen Biotech, Inc. | Generalized Myasthenia Gravis (gMG) | 04/29/2025 | 90:08.04 - Neonatal Fc Receptor Blockers | BLA | 761430 |
| Penpulimab-kcqx | Akeso, Inc. | Advanced Nasopharyngeal Carcinoma | 04/23/2025 | 10:00 - Antineoplastic Agents | BLA/O | 761258 | |
| Vanrafia | atrasentan | Novartis Pharmaceuticals Corp | Proteinuria Reduction in Primary IgA Nephropathy | 04/02/2025 | 48:48.12 - Endothelin receptor antagonists | 1P | 219208 |
| Qfitlia | fitusiran | Genzyme corp | Hemophilia A or B With or Without Inhibitors | 03/28/2025 | 20:28.16 - Hemostatics | 1S/O | 219019 |
| Vykat XR | diazoxide choline | Soleno Therapeutics, Inc. | Hyperphagia in Prader-Willi Syndrome | 03/26/2025 | 28:20.92 - Anorexigenic Agents and Stimulants, Miscellaneous | 2P/O | 216665 |
| Blujepa | gepotidacin | GSK | Uncomplicated Urinary Tract Infections | 03/25/2025 | 8:12.28.36 - Triazaacenaphthylenes | 1P | 218230 |
| Encelto | revakinagene taroretcel-lwey | Neurotech Pharmaceuticals, Inc. | Macular Telangiectasia Type 2 (MacTel) | 03/06/2025 | 26:12 - Gene Therapy; 52:92 - EENT Drugs, Miscellaneous | ||
| Vimkunya | chikungunya vaccine, recombinant | Bavarian Nordic A/S | Prevention of Disease Caused by Chikungunya Virus | 02/14/2025 | 80:12 - Vaccines | ||
| Romvimza | vimseltinib | Ono Pharmaceutical Co., Ltd. | Symptomatic Tenosynovial Giant Cell Tumor | 02/14/2025 | 10:00 - Antineoplastic Agents | 1P | |
| Gomekli | mirdametinib | SpringWorks Therapeutics, Inc. | Adult and Pediatric Patients with NF1-PN | 02/11/2025 | 10:00 - Antineoplastic Agents | ||
| Emblaveo | aztreonam and avibactam | AbbVie | Complicated Intra-Abdominal Infections | 02/07/2025 | 8:12.07.16 - Monobactams | ||
| Symbravo | meloxicam and rizatriptan | Axsome Therapeutics, Inc. | Acute Treatment of Migraine with or without Aura in Adults | 01/30/2025 | 28:32.28 - Selective Serotonin Agonists; 28:08.04.04 - Reversible COX-1/COX-2 Inhibitors | ||
| Journavx | suzetrigine | Vertex Pharmaceuticals | Moderate-to-Severe Acute Pain | 01/30/2025 | 28:08.92 - Analgesics and Antipyretics, Miscellaneous | 1P | |
| Grafapex | treosulfan | Medexus | Allogeneic Hematopoietic Stem Cell Transplantation | 01/22/2025 | 10:00 - Antineoplastic Agents | ||
| Datroway | datopotamab deruxtecan-dlnk | Daiichi Sankyo | Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer | 01/17/2025 | 10:00 - Antineoplastic Agents | BLA | |
| Alhemo | concizumab-mtci | Novo Nordisk | Prevent or Reduce Bleeding Episodes in People with Hemophilia A or B with Inhibitors | 12/20/2024 | 20:28.16 - Hemostatics | BLA | |
| Alyftrek | Vanzacaftor/Tezacaftor/Deutivacaftor | Vertex Pharms INC | Cystic Fibrosis | 12/20/2024 | 48:14.04 - Cystic Fibrosis Transmembrane Conductance Regulator Correctors; 48:14.12 - Cystic Fibrosis Transmembrane Conductance Regulator Potentiators | 1P/O | |
| Tryngolza | olezarsen | Ionis Pharmaceuticals, Inc. | Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome | 12/19/2024 | 24:06.92 - Antilipemic Agents, Miscellaneous | 1P | |
| Ensacove | ensartinib | Xcovery Holdings, Inc. | ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/18/2024 | 10:00 - Antineoplastic Agents | 1S | |
| Ryoncil | remestemcel-L-rknd | Mesoblast, Inc. | steroid-refractory acute graft versus host disease in pediatric patients | 12/18/2024 | 26:04 - Cellular Therapy | ||
| Unloxcyt | cosibelimab-ipdl | Checkpoint Therapeutics, Inc. | Cutaneous Squamous Cell Carcinoma | 12/13/2024 | 10:00 - Antineoplastic Agents | BLA | |
| Crenessity | crinecerfont | Neurocrine Biosciences, Inc. | Classic Congenital Adrenal Hyperplasia | 12/13/2024 | 68:28 - Pituitary | 1P | |
| Bizengri | zenocutuzumab-zbco | Merus N.V. | NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer | 12/04/2024 | 10:00 - Antineoplastic Agents | BLA/O | |
| Iomervu | Iomeprol | Bracco Diagnostics INC | diagnostic imaging procedures with chemical properties similar to another iodinated contrast agent iopromide (nonionic, low osmolality) | 11/27/2024 | 36:68 - Roentgenography | ||
| Rapiblyk | landiolol | AOP Orphan Pharmaceuticals GmbH | Atrial Fibrillation and Atrial Flutter in the Critical Care Setting | 11/22/2024 | 24:20 - beta-Adrenergic Blocking Agents | 1S | |
| Attruby | acoramidis | BridgeBio Pharma, Inc. | Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM | 11/22/2024 | 24:04.92 - Cardiac Drugs, Miscellaneous | 1S/O | |
| Revuforj | revumenib | Syndax Pharmaceuticals | Relapsed or Refractory Acute Leukemia with a KMT2A Translocation | 11/15/2024 | 10:00 - Antineoplastic Agents | 1P | |
| Kebilidi | eladocagene exuparvovec-tneq | PTC Therapeutics, Inc. | AADC Deficiency | 11/13/2024 | 26:12 - Gene Therapy | ||
| Aucatzyl | obecabtagene autoleucel | Autolus Therapeutics plc | Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | 11/08/2024 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | ||
| Orlynvah | sulopenem etzadroxil and probenecid | Iterum Therapeutics plc | Uncomplicated Urinary Tract Infections | 10/25/2024 | 8:36 - Urinary Anti-infectives | 1/4 P | |
| Vyloy | zolbetuximab-clzb | Astellas Pharma Inc. | Advanced Gastric and GEJ Cancer | 10/18/2024 | 10:00 - Antineoplastic Agents | BLA/O | |
| Vyalev | foscarbidopa and foslevodopa | AbbVie | Advanced Parkinson's Disease | 10/16/2024 | 28:36.16 - Dopamine Precursors | 3/4 S/O | |
| Hympavzi | Marstacimab-hncq | Pfizer Inc. | Hemophilia A or B Without Inhibitors | 10/11/2024 | 20:28.16 - Hemostatics | BLA/O | |
| Itovebi | inavolisib | Genentech | Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation | 10/10/2024 | 10:00 - Antineoplastic Agents | S | |
| Flyrcado | flurpiridaz F 18 | GE HealthCare | evaluate for myocardial ischemia (cardiac function disorder when the heart muscle doesn’t receive enough blood flow to function properly) and infarction (heart attack) | 09/27/2024 | 36:68 - Roentgenography | 1S | |
| Cobenfy | xanomeline and trospium chloride | Bristol Myers Squibb | Schizophrenia | 09/26/2024 | 28:16.08.92 - Antipsychotics, Miscellaneous; 86:12.04 - Antimuscarinics | 1P | |
| Aqneursa | levacetylleucine | IntraBio Inc. | Niemann-Pick Disease Type C | 09/24/2024 | 92:92 - Other Miscellaneous Therapeutic Agents | ||
| Miplyffa | arimoclomol | Zevra Therapeutics, Inc. | Niemann-Pick Disease Type C | 09/20/2024 | 44:08 - Enzyme Cofactors/Chaperones | 1P/O | |
| EBGLYSS | lebrikizumab-lbkz | Eli Lilly and Company | Moderate-to-Severe Atopic Dermatitis | 09/13/2024 | 84:06.28 - Immunomodulatory Agents | BLA | |
| Rybrevant Plus Lazcluze | amivantamab-vmjw plus lazertinib | Janssen Biotech, Inc. | EGFR-Mutated Advanced Lung cancer | 08/20/2024 | 10:00 - Antineoplastic Agents |